Rosanna Coppo, Regina Margherita Children‘s Hospital, Nephrology, Dialysis and Transplantation


Rosanna Coppo is presently:

  • Secretary General,  European Society of Paediatric Nephrology  (ESPN) 2012-2015.
  • Coordinator,  ERA-EDTA Immunonephrology Working Group (2009-2015).

Research Focus:

Clinical research area.

New strategies (from bench to bedside) for treating difficult  cases of children with nephrotic syndrome resistant to steroids or dependent from this treatment. Use of antiviral protease inhibitors provided with anti NF-kB activity (Saquinavir, NDT 2012;27:1902-10)

Relevance of your Provisional grouping in KidneyConnect:  

The Group 16TOR-1 is formed by outstanding scientists and clinicians.

The Group hast he possibility of enrolling patients for  focused basic science studies and/or clinical trails derived from new ideas originated from advanced laboratory investigations.

The Leader specific contribution is the capacity/possibility of facilitating  liaisons with Pediatric  and Adult Nephrology Centers in Europe, to offer them the possibility to join interesting new studies.

Resources Available relevant to your grouping

  • Special Techniques
  • Animal Models/Knock Outs
  • Datasets
  • Others: possibility of establishing a European Group  of Pediatric Nephrologists involved in the care of children with idiopathic nephrotic syndrome willing to explore new terapeutic possibilities or  pilot protocols

Clinical/Translational Resources

  • Biobanks
  • Population/Patient Cohorts: YES
  • Special Techniques for Clinical Assessment

  • Presently ongoing focused researches:
  1. Switch from proteasome to immuneproteasome in peripheral blood lymphomonocytes (PBMC) from  children with  nephrotic syndrome
  2. Advanced oxidated protein products (AOPP)  and other oxidative stress markers in circulation in  children with nephrotic syndrome
  3. Treg/Th17 balance in  children  with nephrotic syndrome, focusing on activation of  IDO (Indoleamine-2,3-dioxygenase), an enzyme that catabolises tryptophan and plays  an important immune-regulator role
  • Patient Groups for Clinical trials YES,via ESPN and ERA-EDTA networks
  • Others